Riehen, Switzerland

Johannes Laurenz Kellenberger


 

Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 14(Granted Patents)


Location History:

  • Basel, CH (2006 - 2009)
  • Riehen, CH (2012 - 2019)

Company Filing History:


Years Active: 2006-2019

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovations of Johannes Laurenz Kellenberger

Introduction

Johannes Laurenz Kellenberger is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of macrolide compounds. With a total of 10 patents to his name, Kellenberger's work has had a considerable impact on medicinal chemistry.

Latest Patents

One of Kellenberger's latest patents involves selected macrolides with PDE4-inhibiting activity. The application relates to a macrolide compound of a specific formula, wherein the compound may include a stereocentre in either (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof. These compounds are recognized for their potential use as PDE4 inhibitors, which are important in treating various inflammatory conditions.

Career Highlights

Throughout his career, Kellenberger has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Basilea Pharmaceutica AG and Biotica Technology Limited. His work in these organizations has allowed him to advance his research and contribute to innovative solutions in drug development.

Collaborations

Kellenberger has collaborated with esteemed colleagues, including Jürg Dreier and Stefan Bernhard Reinelt. These partnerships have fostered a collaborative environment that enhances the innovation process in their respective fields.

Conclusion

Johannes Laurenz Kellenberger's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…